The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer: A Meta-analysis
Abstract
CONTEXT: Randomized trials have demonstrated that adding a drug to a single-agent or to a 2-agent regimen increased the tumor response rate in patients with advanced non-small-cell lung cancer (NSCLC), although its impact on survival remains controversial. OBJECTIVE: To evaluate the clinical benefit of adding a drug to a single-agent or 2-agent chemotherapy regimen in terms of tumor response rate, survival, and toxicity in patients with advanced NSCLC. DATA SOURCES AND STUDY SELECTION: Data from all randomized controlled trials performed between 1980 and 2001 (published between January 1980 and October 2003) comparing a doublet regimen with a single-agent regimen or comparing a triplet regimen with a doublet regimen in patients with advanced NSCLC. There were no language restrictions. Searches of MEDLINE and EMBASE were performed using the search terms non-small-cell lung carcinoma/drug therapy, adenocarcinoma, large-cell carcinoma, squamous-cell carcinoma, lung, neoplasms, clinical trial phase III, and randomized trial. Manual searches were also performed to find conference proceedings published between January 1982 and October 2003. DATA EXTRACTION: Two independent investigators reviewed the publications and extracted the data. Pooled odds ratios (ORs) for the objective tumor response rate, 1-year survival rate, and toxicity rate were calculated using the fixed-effect model. Pooled median ratios (MRs) for median survival also were calculated using the fixed-effect model. ORs and MRs lower than unity (<1.0) indicate a benefit of a doublet regimen compared with a single-agent regimen (or a triplet regimen compared with a doublet regimen). DATA SYNTHESIS: Sixty-five trials (13 601 patients) were eligible. In the trials comparing a doublet regimen with a single-agent regimen, a significant increase was observed in tumor response (OR, 0.42; 95% confidence interval [CI], 0.37-0.47; P<.001) and 1-year survival (OR, 0.80; 95% CI, 0.70-0.91; P<.001) in favor of the doublet regimen. The median survival ratio was 0.83 (95% CI, 0.79-0.89; P<.001). An increase also was observed in the tumor response rate (OR, 0.66; 95% CI, 0.58-0.75; P<.001) in favor of the triplet regimen, but not for 1-year survival (OR, 1.01; 95% CI, 0.85-1.21; P =.88). The median survival ratio was 1.00 (95% CI, 0.94-1.06; P =.97). CONCLUSION: Adding a second drug improved tumor response and survival rate. Adding a third drug had a weaker effect on tumor response and no effect on survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205 · cited 1×
“The MantelHaenszel test stratified by trial was used for the treatment effect and the Cochran test was used for heterogeneity.(19) The ORs for tumor response and survival for the doublet regimen vs the singleagent regimen and for the triplet regimen vs the doublet regimen were compared using an interaction test.”
MethodJemal, A., Thomas, A., Murray, T., & Thun, M. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.1.23 · Cited by 2,917
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Le Chevalier, T., Brisgand, D., Douillard, J. Y., Pujol, J. L., Alberola, V, Monnier, A., Riviere, A., Lianes, P., Chomy, P., & Cigolari, S. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.360 · Cited by 811
Self-citationMeta-analysis of the literature or of individual patient data: is there a difference?
Stewart, L. A., & Parmar, M. K. B. (1993) · The Lancet · doi:10.1016/0140-6736(93)93004-k · Cited by 769
Albain, K. S., Crowley, J. J., LeBlanc, M., & Livingston, R. B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1618 · Cited by 728
Sandler, A. B., Nemunaitis, J., Denham, C., von Pawel, J., Cormier, Y., Gatzemeier, U., Mattson, K., Manegold, C., Palmer, M. C., Gregor, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.122 · Cited by 712
Wozniak, A. J., Crowley, J. J., Balcerzak, S. P., Weiss, G. R., Spiridonidis, C. H., Baker, L. H., Albain, K. S., Kelly, K., Taylor, S. A., Gandara, D. R., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2459 · Cited by 555
Polychemotherapy in advanced non small cell lung cancer: a meta-analysis
Bernard, J. P., Souquet, P. J., Boissel, J. P., Chauvin, F., Cellerino, R., Tumarello, D., Cormier, Y., Ganz, P. A., Kaasa, S., Pater, J. L., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)91882-m · Cited by 490
Frasci, G., Lorusso, V., Panza, N., Comella, P., Nicolella, G., Bianco, A., De Cataldis, G., Iannelli, A., Bilancia, D., Belli, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2529 · Cited by 447
Wood, A. J. J., & Ihde, D. C. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272006 · Cited by 428
Bunn, P. A., & Kelly, K. L. (1998) · PubMed · Cited by 400
Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
Grilli, R., Oxman, A. D., & Julian, J. A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1866 · Cited by 382
Breathnach, O. S., Freidlin, B., Conley, B., Green, M. R., Johnson, D. H., Gandara, D. R., O’Connell, M., Shepherd, F. A., & Johnson, B. E. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1734 · Cited by 354
Bonomi, P. D., Finkelstein, D. M., Ruckdeschel, J. C., Blum, R. H., Green, M. D., Mason, B., Hahn, R., Tormey, D. C., Harris, J., & Comis, R. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1602 · Cited by 323
Chemotherapy vs Supportive Care in Advanced Non-Small-Cell Lung Cancer
Marino, P., Pampallona, S., Preatoni, A., Cantoni, A., & Invernizzi, F. (1994) · Chest · doi:10.1378/chest.106.3.861 · Cited by 299
Rosell, R., Gatzemeier, U., Betticher, D. C., Keppler, U., Macha, H. N., Pirker, R., Berthet, P., Breau, J. L., Lianes, P., Nicholson, M., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf332 · Cited by 299
von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L. O., Clark, P., Talbot, D., Rey, A., Butler, T. W., Hirsh, V., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1351 · Cited by 285
Gatzemeier, U., von Pawel, J., Gottfried, M., Velde, G. P. M. T., Mattson, K., DeMarinis, F., Harper, P., Salvati, F., Robinet, G., Lucenti, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3390 · Cited by 226
Depierre, A., Chastang, C. L., Quoix, E., Lebeau, B., Blachon, F., Paillot, N., Lemarie, E., Milleron, B., Moro, D., Clavier, J., et al. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058687 · Cited by 219
Confronting publication bias: A cohort design for meta‐analysis
Simes, R. J. (1987) · Statistics in Medicine · doi:10.1002/sim.4780060104 · Cited by 216
Alberola, V., Camps, C., Provencio, M., Isla, D., Rosell, R., Vadell, C., Bover, I., Ruiz-Casado, A., Azagra, P., Jiménez, U., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.038 · Cited by 193
Michiels, S., Piedbois, P., Burdett, S., Syz, N., Stewart, L., & Pignon, J.-P. (2005) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462305050154 · Cited by 154
Self-citationfor the CPT-11 Lung Cancer Study Group West, Negoro, S., Masuda, N., Takada, Y., Sugiura, T., Kudoh, S., Katakami, N., Ariyoshi, Y., Ohashi, Y., Niitani, H., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600725 · Cited by 151
Gandara, D. R., Crowley, J. J., Livingston, R. B., Perez, E. A., Taylor, C. W., Weiss, G. R., Neefe, J. R., Hutchins, L. F., Roach, R. W., & Grunberg, S. M. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.5.873 · Cited by 150
Klastersky, J. A., Sculier, J., Bureau, G., Libert, P., Ravez, P., Vandermoten, G., Thiriaux, J., Lecomte, J., Cordier, R., & Dabouis, G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1087 · Cited by 130
Einhorn, L. H., Loehrer, P. J., Williams, S. D., Meyers, S., Gabrys, T., Nattan, S. R., Woodburn, R., Drasga, R. E., Songer, J., & Fisher, W. B. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.7.1037 · Cited by 126
Non-small cell lung cancer part: I Biology, diagnosis, and staging
Ihde, D. C., & Minna, J. D. (1991) · Current Problems in Cancer · doi:10.1016/0147-0272(91)90014-2 · Cited by 118
Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma
Lilenbaum, R., LANGENBERG, P. W., & Dickersin, K. (1998) · Cancer · Cited by 112
Luedke, D. W., Einhorn, L. H., Omura, G., Sarma, P. R., Bartolucci, A. A., Birch, R., & Greco, F. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.5.886 · Cited by 77
Fukuoka, M., Masuda, N., Furuse, K., Negoro, S., Takada, M., Matsui, K., Takifuji, N., Kudoh, S., Kawahara, M., & Ogawara, M. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.606 · Cited by 70
Soria, J., Brisgand, D., & Chevalier, T. L. (2001) · Annals of Oncology · doi:10.1023/a:1013574413217 · Cited by 66
Self-citationSouquet, P. J., Tan, E. H., Pereira, J. R., van Klaveren, R., Price, A., Gatzemeier, U., Jaworski, M., Burillon, J. P., & Aubert, D. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf316 · Cited by 62
Edelman, M. J., Quam, H., & Mullins, B. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000273 · Cited by 58
Treatment of Advanced Non–Small-Cell Lung Cancer With Two-Drug Combinations
Bunn, P. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.17.3565 · Cited by 57
Crinò, L., Tonato, M., Darwish, S., Meacci, M. L., Corgna, E., Costanzo, F. D., Buzzi, F., Fornari, G., Santi, E., Ballatori, E., et al. (1990) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf02940294 · Cited by 50
Individual patient data meta‐analysis of randomized anti‐epileptic drug monotherapy trials
Williamson, P. R., Marson, A. G., Smith, C. T., Hutton, J. L., & Chadwick, D. W. (2000) · Journal of Evaluation in Clinical Practice · doi:10.1046/j.1365-2753.2000.00236.x · Cited by 47
Waters, J. S., & O'Brien, M. E. R. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600491 · Cited by 36
Shinkai, T., Eguchi, K., Sasaki, Y., Tamura, T., Ohe, Y., Kojima, A., Oshita, F., & Saijo, N. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90220-8 · Cited by 29
Is cisplatin still the best platinum compound in non-small-cell lung cancer?
Soria, J., & Chevalier, T. L. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf331 · Cited by 23
Self-citationGeorgoulias, V., Pallis, A. G., Kourousis, C., Alexopoulos, A., Ardavanis, A. S., Agelidou, A., Agelidou, M., Toumbis, M., Tzannes, S., Pavlakou, G., et al. (2003) · Clinical Lung Cancer · doi:10.3816/clc.2003.n.008 · Cited by 17
Masutani, M., Akusawa, H., KADOTA, A., Ohchi, Y., Takahashi, N., Tanigawa, S., Koya, Y., & Horie, T. (1996) · Respirology · doi:10.1111/j.1440-1843.1996.tb00010.x · Cited by 15
Gorospe, A., Cristal‐Luna, G., Li, R., et al. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)80225-1 · Cited by 4
Cited by
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878
Self-citationAzzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
Gatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., De Rosa, F., Milanowski, J., Karnicka-Mlodkowski, H., Pesek, M., Serwatowski, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1474 · Cited by 881
Metadata
- Authors
- Delbaldo, C., Michiels, S., Syz, N., Soria, J.-C., Le Chevalier, T., & Pignon, J.-P.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2004-07-28
- Volume
- 292
- Issue
- 4
- Pages
- 470
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2052335855
- Cited by
- 337
- References
- 44
- FWCI
- 18.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.